Adjacent Evidence Brief: Statin Therapy Rates

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Resolve the scope mismatch: either narrow the research question to match the actual corpus (statin effects on clinical outcomes in specific populations) or expand the corpus to include dedicated prescription-rate studies (only 2/21 sources actually measure rates).
2. Complete the truncated Longevity Outcomes section.
3. Reconcile effect-direction coding in the bundle with directional claims in prose; flag any bundle-coded 'unclear' effect directions that the prose treats as positive/negative.
4. Add Ioannidis 2005 to the source bundle or remove the citation from Limitations.
5. Clarify the operational definition of 'significant source statistic' used in the Evidence Landscape table.
6. Reclassify or reframe Musich 2019 and Bao 2024 to reflect their actual design (secondary-prevention utilization cohort and narrative review, respectively).

Major issues

• The research question asks about 'Statin Therapy Rates' but the included evidence bundle is overwhelmingly about statin *effects* (outcomes of statin use in specific disease populations), not about prescription/utilization rates themselves. Only Musich 2019 and Lundholm 2026 actually address prescription rates directly; the remaining 19 sources address downstream outcomes in statin-exposed cohorts. This is a fundamental scope mismatch between the stated question and the curated corpus.
• Several author-year citations in the prose (Bugiardini 2022, Pramana 2023, Sultan 2023, Li 2026) are inconsistently rendered as direct primary studies in the body text but appear in the source bundle as reviews, and their effect directions are coded 'unclear' in the bundle despite prose claims drawing mechanistic or directional inferences from them.
• The Longevity Outcomes section is truncated mid-sentence ('rather than from a single canonical trial...'), indicating an incomplete manuscript render.

Minor issues

• The abstract repeatedly states 'positive study-level signals are not the dominant direction in any outcome class' yet Mortality and Survival table shows 'positive signal in 1/2 sources' and Musich 2019 documents mortality benefit by intensity — phrasing should be tightened.
• Evidence landscape table reports 'significant source statistic in 8/12 sources' for contextual adjacent evidence but does not define what 'significant source statistic' means operationally.
• Bao 2024 is categorized as 'primary' in the bundle but described in prose as a review; Yan 2026 appears in contextual_other but its bundle excerpt concerns MG safety, which overlaps with the safety_comorbidity outcome class.
• Musich 2019 is a secondary-prevention utilization cohort, not an anti-aging study, and its inclusion under the longevity/anti-aging framing should be justified or removed.
• The Limitations section references 'Ioannidis 2005' for surrogate-association caution but Ioannidis 2005 is not in the source bundle and is not listed as a cited reference.

Reviewer note

This rapid evidence synthesis is internally careful and well-bounded in its concluding posture: the conclusion explicitly disclaims causal, clinical, or policy claims and frames the work as a source-traced evidence map. The search summary is explicit (multiple databases, queries, eligibility criteria, and an admission funnel are provided), the limitations section identifies the absence of long-term placebo-controlled RCTs as the central gap, and the explicit outcome-class structure with mapped directness is appropriate for a rapid synthesis. However, the manuscript has a foundational scope problem. The stated question is about 'Statin Therapy Rates' (i.e., prescription/utilization rates), but the bundle is overwhelmingly about outcomes of statin therapy in specific disease cohorts (post-PCI, post-CABG, CKD, T1D, sepsis, etc.). Only Musich 2019 and Lundholm 2026 directly address prescription rates. This mismatch means the synthesis answers a different question than it claims to ask, which materially weakens the research_question_quality and claim_evidence_alignment scores. Additional defects include a truncated Longevity section (manuscript is incomplete), inconsistent effect-direction coding between bundle and prose, and an uncited Ioannidis 2005 reference in Limitations. The synthesis quality is adequate rather than strong because the evidence landscape reads as parallel per-domain summaries with limited cross-domain integration; the cross-source tension analysis is performed but only for the contextual_other class. Source grounding is solid: bundle entries exist for all author-year citations in prose (after allowing for the Bao 2024 / Pramana 2023 / Sultan 2023 / Bugiardini 2022 design-label mismatches noted above), and recent sources within 5 years directly support the bounded claims made. Hedging language is appropriate throughout and reflects honest engagement with the indirect, mixed evidence base. Recommendation: revise. The manuscript is salvageable with bounded edits: complete the truncated section, resolve the scope mismatch between question and corpus (either reframe the question or expand the corpus), reconcile effect-direction coding, and add the missing Ioannidis citation. The bounded conclusion posture is correct and should be preserved.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis